Searching map area
Tamoxifen
? TBD
Medication
Join to rate
Ratings 0
Nobody has rated this yet. Be the first!
Subject of 13
Tamoxifen-induced radiation recall dermatitis
scientific article published in March 2004
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
scientific article
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
scientific article published on June 2004
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
scientific article published on 10 August 2011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
scientific article published in The Lancet
Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients
scientific article
Tamoxifen induced radiation recall dermatitis in a breast cancer patient
scientific article
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
scientific article published in February 2005
Tamoxifen-induced radiation recall dermatitis
scientific article published on 15 February 2017
Tamoxifen-induced radiation recall dermatitis
scientific article published on 01 December 2006
Lists 0
Join to rate
Wikipedia

Tamoxifen, sold under the brand name Nolvadex among others, is a selective estrogen receptor modulator used to prevent breast cancer in women and men. It is also being studied for other types of cancer. It has been used for Albright syndrome. Tamoxifen is typically taken daily by mouth for five years for breast cancer.

Instance of
type of chemical entity
Subclass of
Chemical compound
References
Wikidata